GlassScriptPhysician profile
Jamie M Brinson
NPI 1013787639
$1,734.84
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,734.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $419.84 | 2024 | |
| Lilly USA, LLC | $255.46 | 2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $201.07 | 2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $149.32 | 2024 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $115.27 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $104.42 | 2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Tris Pharma INC | $84.63 | 2024 | Dyanavel Xr |
| Bayer Healthcare Pharmaceuticals INC. | $67.59 | 2024 | |
| Pfizer INC. | $62.60 | 2024 | |
| Phathom Pharmaceuticals, INC. | $52.05 | 2024 | Voquezna |
| Amgen INC. | $43.07 | 2024 | Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.91 | 2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $30.88 | 2024 | Trintellix |
| Corium, LLC | $22.70 | 2024 | Azstarys |
| Inari Medical, INC. | $16.75 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $15.64 | 2024 | |
| Paratek Pharmaceuticals, INC. | $15.36 | 2024 | Nuzyra |
| Corcept Therapeutics | $14.75 | 2024 | Korlym |
| Regeneron Healthcare Solutions, INC. | $14.04 | 2024 | Evkeeza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.49 | 2024 | Synjardy, Jardiance, Tradjenta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Brinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.